PATENT CLAIM ANALYSIS

Application Number: 16040012
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "294000"]

Abstract:
Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.

Claim (Index 10):
A method of treating abnormal involuntary movement in a subject having a movement disorder, said method comprising administering an initial daily amount of deutetrabenazine of about 6 mg/day to about 48 mg/day, in one or two doses, to the subject, wherein:\n a) the abnormal involuntary movement is reduced in said subject; and b) one or more symptom of depression, insomnia, somnolence, fatigue, dizziness, restlessness, agitation, akathisia, parkinsonism, nausea, anxiety, impaired swallowing, body weight gain, irritability, or compulsive behavior is improved in said subject.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 95.0
- Lexical Diversity: 1.16667
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14900028', '11355339', '12638227', '14307195', '11340802']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7003963610727607
- 35 USC 102 Novelty (BERT): 0.5235522476246315
- Combined Prediction Score: 0.6827119497279478
- Mean Citation Score: 254.932838
- Max Citation Score: 300.44366
- Similarity Product: 202.0006412605989

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test